CN

About Us

CSPC INNOVATION PHARMACEUTICAL CO.,LTD

CSPC Innovation Pharmaceutical Co., Ltd. (formerly CSPC Xinnuowei Pharmaceutical Co., Ltd., hereinafter referred to as "CSPC Innovation") is a subsidiary of CSPC Pharmaceutical Group (stock code: 1093.HK), a constituent stock of the Hang Seng Index in Hong Kong. It has now developed into an innovative company integrating biopharmaceuticals, active pharmaceutical ingredients, and functional foods.

  • 2006
    Xinnuowei (former name) company established
  • 2016
    Acquired CSPC Zhongnuo Pharmaceutical (Taizhou) Co., Ltd.; acquired Hebei Zhongnuo Guoweikang Health Products Co. Ltd.
  • 2019
    Listed on the ChiNext board of the A-shares, stock code: 300765.SZ）
  • 2020
    Awarded the "Most Promising Listed Company" title
  • 2021
    Acquired CSPC Shengxue
  • 2022
    Selected as one of the "Top 100 Most Trusted Food Companies in China"
  • 2023
    Renamed "CSPC Innovation"
  • 2024
    Increased capital in CSPC Megalith;
    included in the FTSE Russell Global Equity Index Series;
    launched Omalizumab for Injection;
    listed Class 1 new drug Enlonstobart Injection
  • 2025
    Rated as a National Green Factory;
    SYS6010 included in the List of Breakthrough Therapy Designation;
    SYS6017 shingles mRNA vaccine approved for clinical trials;
    signed an exclusive cooperation agreement with Radiance Biopharma

  • Biopharmaceutical field

    CSPC Innovation relying on an advanced technology platform for innovative drug research and development, has made breakthroughs in cutting-edge biopharmaceutical areas such as antibody drugs, antibody-drug conjugates (ADCs), and mRNA vaccines. It has already launched China's first mRNA vaccine, the country's first biosimilar of Xolair® (Omalizumab for Injection) developed under Class 3.3 therapeutic biological products, as well as the Class 1 new biological drug PD-1 inhibitor Enshuxing®.

    More

  • Functional ingredients and APIs

    CSPC Innovation’s product line primarily includes caffeine, acarbose, anhydrous glucose raw materials, as well as Guoweikang vitamin C tablets and B-complex vitamin tablets. Among them, CSPC's caffeine production scale and market share are among the top globally, serving as a global supplier for the three major international beverage companies: Pepsi, Coca-Cola, and Red Bull. The company is also in the first tier of China's health food industry, having created the popular vitamin C tablet brand Guoweikang, loved by consumers.

    Functional Foods Active Pharmaceutical Ingredient (APIs)

At present, CSPC Innovation has gained recognition in the global market. Its products have received certifications such as GMP, ISO system, BRC, and KOSHER. Backed by a well-established overseas sales network, the company maintains a diversified presence in markets across North America, South America, Europe, and South Asia, with products distributed to numerous countries and regions worldwide. At the same time, the company has established a sustainable development management system and actively advances initiatives related to carbon inventory, carbon verification, and carbon footprint. It has also received a Silver rating from the Ecovadis evaluation system.

As an innovation-driven company, CSPC Innovation will continue to uphold R&D as its core engine in the future. With biopharmaceuticals and functional foods (ingredients) as its dual pillars, the company will deepen its presence in the healthcare industry, strive to enhance the international core competitiveness of China's biopharmaceutical industry, and contribute to the overall improvement of national health.



  • CSPC Innovative Pharmaceutical Co., Ltd.

  • CSPC Megalith Biopharmaceutical Co., Ltd.

  • CSPC SHENGXUE GLUCOSE CO., LTD.

  • CSPC ZHONGNUO PHARMACEUTICAL (TAIZHOU) CO., LTD.

  • CSPC Innovative Pharmaceutical Co., Ltd.

    CSPC Innovative Pharmaceutical Co., Ltd. is a subsidiary of CSPC Group, located at No. 62 Zhangju Road, Luancheng District, Shijiazhuang. The company was established in 1989, converted into a joint-stock enterprise in 2006, and was listed on the Shenzhen Stock Exchange in 2019. It covers a total area of 112,000 square meters. The company has a registered capital of 546 million yuan and currently employs over 800 people.

    More
  • CSPC Megalith Biopharmaceutical Co., Ltd.

    CSPC Megalith Biopharmaceutical Co., Ltd. was founded in 2019 and is located in Shijiazhuang International Biomedical Industry Park. In accordance with international high standards, the company has built a high-tech industrialization base for innovative biopharmaceuticals with independent intellectual property rights.

    More
  • CSPC SHENGXUE GLUCOSE CO., LTD.

    Founded in 1991, the company is a wholly-owned subsidiary of CSPC Pharmaceutical Group. It has two manufacturing campuses (north and south) covering a total area of approximately 84,666.7 square meters (127 Chinese mu), and mainly produces a series of products including acarbose and anhydrous glucose. It currently has over 500 employees.

    More
  • CSPC ZHONGNUO PHARMACEUTICAL (TAIZHOU) CO., LTD.

    The factory area of Zhongnuo Taizhou Company covers a total area of 115,533.3 square meters (equivalent to 173.3 Chinese mu). It is planned to include 1 comprehensive office building, 1 GSP-compliant warehouse, 1 high-rise automated warehouse, 1 power workshop and 5 production workshops, with a total planned construction area of approximately 140,000 square meters.

    More